These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 26268894)

  • 1. Response to Y. Sasaki et al.: Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?
    Okusaka T; Ikeda M; Fukutomi A; Ioka T; Furuse J; Ohkawa S; Isayama H; Boku N
    Cancer Sci; 2015 Aug; 106(8):1101-2. PubMed ID: 26268894
    [No Abstract]   [Full Text] [Related]  

  • 2. Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?
    Sasaki Y; Hamada K; Kaneta T; Takahashi T; Kubota Y; Ishida H; Ichikawa W
    Cancer Sci; 2015 Aug; 106(8):1100. PubMed ID: 26268893
    [No Abstract]   [Full Text] [Related]  

  • 3. Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy.
    Guion-Dusserre JF; Bertaut A; Ghiringhelli F; Vincent J; Quipourt V; Marilier S; Tharin Z; Bengrine-Lefevre L
    World J Gastroenterol; 2016 Nov; 22(42):9378-9386. PubMed ID: 27895425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nationwide Multicenter Observational Study of FOLFIRINOX Chemotherapy in 399 Patients With Unresectable or Recurrent Pancreatic Cancer in Japan.
    Todaka A; Mizuno N; Ozaka M; Ueno H; Kobayashi S; Uesugi K; Kobayashi N; Hayashi H; Sudo K; Okano N; Horita Y; Kamei K; Yukisawa S; Nakamori S; Yachi Y; Henmi T; Kobayashi M; Boku N; Mori K; Fukutomi A
    Pancreas; 2018; 47(5):631-636. PubMed ID: 29683973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting a response to FOLFIRINOX in pancreatic cancer.
    Nipp RD; Ryan DP
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 26025325
    [No Abstract]   [Full Text] [Related]  

  • 6. Complete pathological response after FOLFIRINOX for locally advanced pancreatic cancer. The beginning of a new era? Case report and review of the literature.
    Valeri S; Borzomati D; Nappo G; Perrone G; Santini D; Coppola R
    Pancreatology; 2014; 14(5):425-30. PubMed ID: 25278312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Two cases of pancreatic cancer treated with FOLFIRINOX regimen and G-CSF prophylaxis at the standard therapeutic dose].
    Kiba T; Okada Y; Kajiume S; Yamaguchi A
    Gan To Kagaku Ryoho; 2015 May; 42(5):629-32. PubMed ID: 25981661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOLFIRINOX: a new standard treatment for advanced pancreatic cancer?
    Kim R
    Lancet Oncol; 2011 Jan; 12(1):8-9. PubMed ID: 21050812
    [No Abstract]   [Full Text] [Related]  

  • 9. Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma.
    Khushman M; Dempsey N; Maldonado JC; Loaiza-Bonilla A; Velez M; Carcas L; Dammrich D; Hurtado-Cordovi J; Parajuli R; Pollack T; Harwood AP; Macintyre J; Tzeng CW; Merchan JR; Restrepo MH; Akunyili II; Ribeiro A; Narayanan G; Portelance L; Sleeman D; Levi JU; Lima CM; Hosein PJ
    Pancreatology; 2015; 15(6):667-73. PubMed ID: 26412296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A case of post-operative recurrence of pancreatic cancer in the residual pancreas treated by resection of the residual pancreas following radiological complete response achieved with second-line FOLFIRINOX].
    Kobayashi N; Shimamura T; Tokuhisa M; Goto A; Mori R; Matsuyama R; Taniguchi K; Tanaka K; Akiyama H; Endo I; Ichikawa Y
    Gan To Kagaku Ryoho; 2014 Jul; 41(7):901-4. PubMed ID: 25131881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful chemotherapy with modified FOLFIRINOX for pancreatic acinar cell carcinoma.
    Hashimoto M; Hikichi T; Suzuki T; Tai M; Ichii O; Matsuhashi N; Kita E; Takahashi S; Okubo Y; Hakozaki H; Ejiri Y; Ohira H
    Clin J Gastroenterol; 2017 Dec; 10(6):564-569. PubMed ID: 29052123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.
    Nywening TM; Wang-Gillam A; Sanford DE; Belt BA; Panni RZ; Cusworth BM; Toriola AT; Nieman RK; Worley LA; Yano M; Fowler KJ; Lockhart AC; Suresh R; Tan BR; Lim KH; Fields RC; Strasberg SM; Hawkins WG; DeNardo DG; Goedegebuure SP; Linehan DC
    Lancet Oncol; 2016 May; 17(5):651-62. PubMed ID: 27055731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Palliative chemotherapy for pancreatic adenocarcinoma: a retrospective cohort analysis of efficacy and toxicity of the FOLFIRINOX regimen focusing on the older patient.
    Berger AK; Haag GM; Ehmann M; Byl A; Jäger D; Springfeld C
    BMC Gastroenterol; 2017 Dec; 17(1):143. PubMed ID: 29207968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia: A Population-based Retrospective Study.
    Ho MY; Kennecke HF; Renouf DJ; Cheung WY; Lim HJ; Gill S
    Am J Clin Oncol; 2017 Dec; 40(6):552-554. PubMed ID: 26165420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOLFIRINOX: a great leap forward, but for whom?
    dos Santos LV; de Andrade DP; Lima JP
    J Clin Oncol; 2012 Jan; 30(1):114-5; author reply 114. PubMed ID: 22124105
    [No Abstract]   [Full Text] [Related]  

  • 16. [Therapy of locally advanced pancreatic cancer with FOLFIRINOX].
    Strobel O; Büchler MW
    Chirurg; 2016 Aug; 87(8):699. PubMed ID: 27418266
    [No Abstract]   [Full Text] [Related]  

  • 17. Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience.
    Nitsche U; Wenzel P; Siveke JT; Braren R; Holzapfel K; Schlitter AM; Stöß C; Kong B; Esposito I; Erkan M; Michalski CW; Friess H; Kleeff J
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1212-20. PubMed ID: 26350368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.
    Stein SM; James ES; Deng Y; Cong X; Kortmansky JS; Li J; Staugaard C; Indukala D; Boustani AM; Patel V; Cha CH; Salem RR; Chang B; Hochster HS; Lacy J
    Br J Cancer; 2016 Mar; 114(7):737-43. PubMed ID: 27022826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A Pancreatic Cancer Patient in Whom Pegfilgrastim Prophylaxis Did Not Prevent Severe Neutropenia Caused by the FOLFIRINOX Regimen].
    Kiba T; Saito Y; Otomo C; Sato M; Meguro T
    Gan To Kagaku Ryoho; 2016 Jul; 43(7):913-5. PubMed ID: 27431641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uptake and Effectiveness of FOLFIRINOX for Advanced Pancreatic Cancer: a Population-based Study.
    Karim S; Zhang-Salomans J; Biagi JJ; Asmis T; Booth CM
    Clin Oncol (R Coll Radiol); 2018 Jan; 30(1):e16-e21. PubMed ID: 29137884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.